glp-1 vagus nerve Increasing GLP‐1 Circulating Levels by Bariatric Surgery or by GLP‐1 Receptor Agonists Therapy: Why Are the Clinical Consequences so Different? - Amouyal - 2016 - Journal of Diabetes Research GLP-1 and the Gut: Natural

These vary in dosing frequencyfrom daily to once weeklyand in their specific receptor binding profiles, which may influence individual response rates and tolerability

Heres what the research and my clinical experience reveal: Semaglutide is a well-established option with: Weekly injections Proven safety profile Average weight loss of 15-20% of body weight Effective appetite suppression Improvements in cardiovascular health markers Tirzepatide offers: Weekly injections Potentially greater weight loss (16-22.5% of body weight) Dual-action mechanism Similar side effect profile to semaglutide Enhanced metabolic benefits In a recent head-to-head trial , tirzepatide demonstrated superior weight loss compared to semaglutide, with participants losing an average of 20.2% versus 13.7% of their body weight at 72 weeks

Additionally, individuals who are overweight and embark on a weight loss journey may experience decreased levels of certain hormones associated with cancer risk, such as estrogens, insulin, and androgens

Circulation 2024;149:450e62

Protective effects of ethanolic extract of Emblica officinalis (amla) on cardiovascular pathophysiology of rats, fed with a high-fat diet